BMG LABTECH and InvivoSciences, Inc. Initiate Market Collaboration to Accelerate Drug Discovery in Engineered 3D Tissues(PresseBox) (Cary, NC, )
In addition, InvivoSciences, Inc. is sponsoring a workshop during Cell Based Assays Summit in Munich Germany, December 02-04, 2013. BMG LABTECH will have a short presentation at the workshop to discuss applications of microplate readers in cell and tissue based assays http://www.assayssummit.com/AgendaDay.aspx?tp_day=40163.
While on January 20th 2014, InvivoSciences and BMG LABTECH will be presenting a workshop tutorial at Society for Laboratory Automation and Screening (SLAS) in San Diego, CA.
These Workshops will highlight applications of pluripotent cells and engineered tissues in drug discovery, including disease model generation as well as personalized and regenerative medicine. Cost-effective and flexible approaches of pluripotent cell culture and its scale up procedures will be presented.
"InvivoSciences has established themselves as a leader in engineered 3D tissues using pluripotent stem cells," said E.J. Dell, Ph.D., International Marketing Director of BMG LABTECH. "We are pleased to partner with them to create a drug discovery platform that is biologically more relevant to researchers."
Ayla Annac, Co-founder and CEO of InvivoSciences comments, "We are especially proud and pleased to establish a long-term relationship with the leading developer and internationally-recognized manufacture of microplate readers, BMG LABTECH."
InvivoSciences, Inc. (IVS) is discovering, developing, and commercializing 3D tissue-based high content analysis technology for drug discovery including drug repositioning, improving drug safety, and developing personalized medicine to improve human health.